Abstract:OBJECTIVE:This study was designed to examine the impact of the antioxidant metallothionein (MT) on cardiac contractile, intracellular Ca(2+) function and oxidative stress in lipopolysaccharide (LPS)-treated mice.METHODS:Weight and age matched adult male FVB and cardiac-specific MT-overexpressing transgenic mice were injected intraperitoneally with 4 mg/kg Escherichia Coli LPS dissolved in sterile saline or an equivalent volume of pathogen-free saline (control groups). Six hours following LPS or saline injection, cardiac geometry and function were evaluated in anesthetized mice using the 2-D guided M-mode echocardiography. Mechanical and intracellular Ca(2+) properties were examined in hearts. Cell shortening and relengthening were assessed using the following indices: peak shortening (PS)-indicative of the amplitude a cell can shorten during contraction; maximal velocities of cell shortening and relengthening (± dl/dt)-indicative of peak ventricular contractility; time-to-PS (TPS)-indicative of systolic duration; time-to-90% relengthening (TR(90))-indicative of diastolic duration (90% rather 100% relengthening was used to avoid noisy signal at baseline concentration). The 360 nm excitation scan was repeated at the end of the protocol and qualitative changes in intracellular Ca(2+) concentration were inferred from the ratio of fura-2 fluorescence intensity (FFI) at two wavelengths (360/380). Fluorescence decay time was measured as an indicator of the intracellular Ca(2+) clearing rate. Glutathione/glutathione disulfide ratio and ROS generation were detected as the markers of oxidative stress.RESULTS:Heart rate was increased while EF was reduced in LPS-FVB mice and heart rate was reduced and EF increased in MT-LPS transgenic mice [(528 ± 72) beats/min vs (557 ± 69) beats/min, (66 ± 14)% vs (42 ± 10)%, P < 0.05]. Cardiomyocytes from the LPS treated FVB mice displayed significantly reduced peak shortening (PS) and maximal velocity of shortening/relengthening (±dl/dt) associated with prolonged time-to-90% relengthening (TR(90)), these effects were attenuated in cardiomyocytes from the MT-LPS mice [PS(5 ± 1.1)% vs (7.2 ± 0.8)%, dl/dt(160 ± 15) µm/s vs (212 ± 36) µm/s, -dl/dt (175 ± 32) µm/s vs (208 ± 29) µm/s, TR(90) (0.24 ± 0.03)s vs (0.19 ± 0.02)s, P < 0.05]. LPS treated mice showed significantly reduced peak intracellular Ca(2+) and electrically-stimulated rise in intracellular Ca(2+) as well as prolonged intracellular Ca(2+) decay rate without affecting the basal intracellular Ca(2+) levels, again, these effects were significantly attenuated in MT-LPS transgenic mice. Metallothionein overexpression also ablated oxidative stress [reduced ROS generation and increased glutathione/glutathione disulfide ratio, ROS (0.35 ± 0.08) A/µg protein vs (0.24 ± 0.03) A/µg protein]. GSH/GSSG 2.1 ± 0.2 vs 2.6 ± 0.4, P < 0.05.CONCLUSION:MT overexpression improved cardiac function and ablated oxidative stress in LPS treated mice.

Metallothionein As a Compensatory Component Prevents Intermittent Hypoxia-Induced Cardiomyopathy in Mice.

Metallothionein Deletion Exacerbates Intermittent Hypoxia-Induced Renal Injury in Mice.

Intermittent Hypoxia-Induced Cardiomyopathy and Its Prevention by Nrf2 and Metallothionein.

Metallothionein Prevents Intermittent Hypoxia-Induced Cardiac Endoplasmic Reticulum Stress and Cell Death Likely Via Activation of Akt Signaling Pathway in Mice.

Deletion of Metallothionein Exacerbates Intermittent Hypoxia-Induced Oxidative and Inflammatory Injury in Aorta.

Nrf2 Protects From Intermittent Hypoxia-induced Cardiomyopathy via Metallothionein-dependent and Independent Mechanisms

Antiapoptotic Effect and Inhibition of Ischemia/Reperfusion-Induced Myocardial Injury in Metallothionein-Overexpressing Transgenic Mice

[Protective Effects of Antioxidants on Chronic Intermittent Hypoxia-Induced Cardiac Remodeling in Mice].

Metallothionein Alleviates Glutathione Depletion-Induced Oxidative Cardiomyopathy in Murine Hearts

Effects of chronic intermittent hypoxia on left cardiac function in young and aged mice

Hypoxia‐inducible Factor 1α is Critically Involved in Metallothionein Protection Against Diabetic Cardiomyopathy

Metallothionein Protects Against Doxorubicin-Induced Cardiomyopathy Through Inhibition of Superoxide Generation and Related Nitrosative Impairment

Intermittent Hypoxia-Induced Renal Antioxidants and Oxidative Damage in Male Mice: Hormetic Dose Response

The Effect of Short-Term Intermittent Hypoxia Exposure on Mouse Myocardial Oxidative Stress and Cardiac Function

Cardiac Metallothionein Overexpression Improves Cardiac Contractile Function and Attenuates Oxidative Stress in Lipopolysaccharide-Treated Mice

Metallothionein Prevents High-Fat Diet-Induced Cardiac Contractile Dysfunction - Role Of Peroxisome Proliferator-Activated Receptor Gamma Coactivator 1 Alpha And Mitochondrial Biogenesis

Increased Oxidative Stress is Associated with Chronic Intermittent Hypoxia-Mediated Brain Cortical Neuronal Cell Apoptosis in a Mouse Model of Sleep Apnea

Metallothionein Alleviates Cardiac Dysfunction in Streptozotocin-Induced Diabetes: Role of Ca2+ Cycling Proteins, NADPH Oxidase, Poly(adp-Ribose) Polymerase and Myosin Heavy Chain Isozyme

Cardiac Protection by Metallothionein Against Ischemia-Reperfusion Injury and Its Possible Relation to Ischemic Preconditioning

Metallothionein Alleviates Oxidative Stress-Induced Endoplasmic Reticulum Stress and Myocardial Dysfunction

Cardiac overexpression of metallothionein rescues cardiac contractile dysfunction and endoplasmic reticulum stress but not autophagy in sepsis